AR033562A1 - BICYCLIC HETEROCICLES, MEDICATIONS CONTAINING THESE COMPOUNDS, THEIR EMPLOYMENT AND PROCEDURES FOR THEIR PREPARATION - Google Patents
BICYCLIC HETEROCICLES, MEDICATIONS CONTAINING THESE COMPOUNDS, THEIR EMPLOYMENT AND PROCEDURES FOR THEIR PREPARATIONInfo
- Publication number
- AR033562A1 AR033562A1 ARP010104041A ARP010104041A AR033562A1 AR 033562 A1 AR033562 A1 AR 033562A1 AR P010104041 A ARP010104041 A AR P010104041A AR P010104041 A ARP010104041 A AR P010104041A AR 033562 A1 AR033562 A1 AR 033562A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- amino
- methyl
- oxo
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Suspension/Interruption
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Heterociclos bicíclicos de la formula general (1), en la que Ra significa un grupo bencilo o 1-feniletilo, o un grupo fenilo sustituido con los radicales R1 y R2, en donde R1 representa un átomo de hidrogeno, fluor, cloro o bromo, un grupo metilo, trifluorometilo, ciano o etinilo, y R2 representa un átomo de hidrogeno o fluor, uno de los radicales Rb o Rc significa un grupo R3-(CH2)m-O, y el otro de los radicales Rb o Rc significa un grupo metoxi, ciclobutiloxi, ciclpentiloxi, ciclopropilmetoxi, ciclobutilmetoxi, ciclopentilmetoxi, tetrahidrofuran-3-il-oxi, tetrahidropiran-3-iloxi, tetrahidropiran-4-iloxi, tetrahidrofuranilmetoxi o tetrahidropiranilmetoxi, representando: R3 un grupo N-(2-oxo-tetrahidrofuran-4-il)-metilamino o N-(2-oxo-tetrahidrofuran-4-il)-etilamino, un grupo R4-O-CO-CH2-N-CH2CH2-OH sustituido en los grupos metileno con uno o dos grupos metilo o etilo, en el que R4 representa un átomo de hidrogeno o un grupo alquilo C1-4, o un grupo 2-oxo-morfolin-4-ilo sustituido con uno o dos grupos metilo o etilo, y m significa el numero 2, 3 o 4; con la condicion de estén excluidos los siguientes compuestos 4-[(3-cloro-4-fluoro-fenil)amino]-6-ciclopentiloxi-7-(2-{N-2-hidroxi-2-metil-prop-1-il)-N-[(etoxicarbonil)metil]-amino}-etoxi)-quinazolina, 4-[(3-cloro-4-fluoro-fenil)amino]-6-ciclopentiloxi-7-[2-(6,6-dimetil-2-oxo-morfolin-4-il)-etoxi]-quinazolina, 4-[(3-bromo-fenil)amino]-6-[2-(6,6-dimetil-2-oxo-morfolin-4-il)-etoxi]-7-metoxi-quinazolina y 4-[(3-bromo-fenil)amino]-6-{2-[N-(2-oxo-tetrahidrofuran-4-il)-N-metil-amino]-etoxi}-7-metoxi-quinazolina, sus tautomeros, sus estereoisomeros y sus sales, en particular sus sales fisiologicamente compatibles con ácidos o bases inorgánicos u orgánicos. Estos compuestos presentan valiosas propiedades farmacologicas, en particular, un efecto inhibidor sobre la transduccion de senales inducida por tirosina-quinasas. También se describe un procedimiento para preparar los compuestos de formula general (1), un medicamento que los contiene y un procedimiento para preparar tal medicamento. Asimismo se describe el uso de los compuestos de formula (1) para preparar un medicamento destinado al tratamiento de tumores benignos o malignos, a la prevencion y al tratamiento de enfermedades de las vías respiratorias y de los pulmones, al tratamiento de polipos, de enfermedades del tracto gastrointestinal, de los conductos biliares y la vesícula biliar, así como de los rinones y la piel.Bicyclic heterocycles of the general formula (1), in which Ra means a benzyl or 1-phenylethyl group, or a phenyl group substituted with the radicals R1 and R2, wherein R1 represents a hydrogen, fluorine, chlorine or bromine atom, a methyl, trifluoromethyl, cyano or ethynyl group, and R2 represents a hydrogen or fluorine atom, one of the radicals Rb or Rc means a group R3- (CH2) mO, and the other of the radicals Rb or Rc means a methoxy group , cyclobutyloxy, cyclopentyloxy, cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, tetrahydrofuran-3-yl-oxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuranylmethoxy or tetrahydropyranylmethoxy, representing: R-3-tetra N-4-tetra N-group -yl) -methylamino or N- (2-oxo-tetrahydrofuran-4-yl) -ethylamino, an R4-O-CO-CH2-N-CH2CH2-OH group substituted in the methylene groups with one or two methyl or ethyl groups , wherein R4 represents a hydrogen atom or a C1-4 alkyl group, or a substituted 2-oxo-morpholin-4-yl group with one or two methyl or ethyl groups, and m means the number 2, 3 or 4; with the proviso that the following compounds 4 - [(3-chloro-4-fluoro-phenyl) amino] -6-cyclopentyloxy-7- (2- {N-2-hydroxy-2-methyl-prop-1-) are excluded il) -N - [(ethoxycarbonyl) methyl] -amino} -ethoxy) -quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6-cyclopentyloxy-7- [2- (6.6 -dimethyl-2-oxo-morpholin-4-yl) -ethoxy] -quinazoline, 4 - [(3-bromo-phenyl) amino] -6- [2- (6,6-dimethyl-2-oxo-morpholin) 4-yl) -ethoxy] -7-methoxy-quinazoline and 4 - [(3-bromo-phenyl) amino] -6- {2- [N- (2-oxo-tetrahydrofuran-4-yl) -N-methyl -amino] -ethoxy} -7-methoxy-quinazoline, its tautomers, its stereoisomers and its salts, in particular its physiologically compatible salts with inorganic or organic acids or bases. These compounds have valuable pharmacological properties, in particular, an inhibitory effect on signal transduction induced by tyrosine kinases. A procedure for preparing the compounds of general formula (1), a medicament containing them and a method for preparing such medicament is also described. The use of the compounds of formula (1) to prepare a medicament for the treatment of benign or malignant tumors, for the prevention and treatment of diseases of the respiratory tract and lungs, for the treatment of polyps, of diseases is also described. of the gastrointestinal tract, bile ducts and gallbladder, as well as the kidneys and skin.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10042058A DE10042058A1 (en) | 2000-08-26 | 2000-08-26 | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR033562A1 true AR033562A1 (en) | 2003-12-26 |
Family
ID=7653945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010104041A Suspension/Interruption AR033562A1 (en) | 2000-08-26 | 2001-08-24 | BICYCLIC HETEROCICLES, MEDICATIONS CONTAINING THESE COMPOUNDS, THEIR EMPLOYMENT AND PROCEDURES FOR THEIR PREPARATION |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP1315705A1 (en) |
| JP (1) | JP4834282B2 (en) |
| KR (1) | KR100862873B1 (en) |
| CN (1) | CN100404517C (en) |
| AR (1) | AR033562A1 (en) |
| AU (2) | AU8769401A (en) |
| BG (1) | BG107559A (en) |
| BR (1) | BR0113519A (en) |
| CA (1) | CA2417897C (en) |
| CZ (1) | CZ302567B6 (en) |
| DE (1) | DE10042058A1 (en) |
| EA (1) | EA005679B1 (en) |
| EC (1) | ECSP034464A (en) |
| EE (1) | EE05269B1 (en) |
| HK (1) | HK1057557A1 (en) |
| HR (1) | HRP20030138A2 (en) |
| HU (1) | HUP0300819A3 (en) |
| IL (2) | IL154602A0 (en) |
| ME (1) | MEP58708A (en) |
| MX (1) | MXPA03001483A (en) |
| MY (1) | MY126132A (en) |
| NO (1) | NO324866B1 (en) |
| NZ (1) | NZ524668A (en) |
| PL (1) | PL360248A1 (en) |
| RS (1) | RS52279B (en) |
| SK (1) | SK287747B6 (en) |
| TW (1) | TWI294422B (en) |
| UA (1) | UA73004C2 (en) |
| UY (1) | UY26903A1 (en) |
| WO (1) | WO2002018351A1 (en) |
| ZA (1) | ZA200300991B (en) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100709909B1 (en) | 1999-06-21 | 2007-04-24 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | Bicyclic heterocycles, medicaments containing these compounds and methods for the production thereof |
| DE10042059A1 (en) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| TW200813014A (en) | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
| DE10214412A1 (en) * | 2002-03-30 | 2003-10-09 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and process for their preparation |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| AU2003226705B2 (en) * | 2002-03-30 | 2008-11-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 4-(N-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors |
| ES2400339T3 (en) | 2002-07-15 | 2013-04-09 | Symphony Evolution, Inc. | Compounds, pharmaceutical compositions thereof and their use in the treatment of cancer |
| DE10326186A1 (en) * | 2003-06-06 | 2004-12-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
| DE10334226A1 (en) * | 2003-07-28 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
| GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| US8318752B2 (en) | 2003-09-19 | 2012-11-27 | Astrazeneca Ab | 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoyl-methyl)piperidin-4-yl]oxy}quinazoline, its pharmaceutically acceptable salts, and pharmaceutical compositions comprising the same |
| JP4638436B2 (en) | 2003-09-26 | 2011-02-23 | エグゼリクシス， インコーポレイテッド | c-Met modulators and uses thereof |
| DE10345875A1 (en) * | 2003-09-30 | 2005-04-21 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, pharmaceutical compositions containing them, their use and methods of preparation |
| US7456189B2 (en) | 2003-09-30 | 2008-11-25 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
| DE10350717A1 (en) * | 2003-10-30 | 2005-06-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| PE20060777A1 (en) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES |
| WO2006090163A1 (en) | 2005-02-26 | 2006-08-31 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
| KR100673775B1 (en) * | 2005-04-08 | 2007-01-24 | 엘지전자 주식회사 | Home bar door of refrigerator |
| WO2007023073A2 (en) * | 2005-08-22 | 2007-03-01 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof |
| US8404697B2 (en) | 2005-11-11 | 2013-03-26 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
| CA2643363A1 (en) * | 2006-03-09 | 2007-09-13 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and process for preparing them |
| NZ576065A (en) | 2006-09-18 | 2011-12-22 | Boehringer Ingelheim Int | Method for treating cancer harboring egfr mutations |
| EP1921070A1 (en) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation |
| MX2009007610A (en) | 2007-02-06 | 2009-07-24 | Boehringer Ingelheim Int | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof. |
| SI2245026T1 (en) | 2008-02-07 | 2012-12-31 | Boehringer Ingelheim International Gmbh | Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production |
| BRPI0912170A2 (en) | 2008-05-13 | 2015-10-13 | Astrazeneca Ab | compound, form, process for preparation thereof, pharmaceutical composition, use of a compound, and method for treating cancer in a warm-blooded animal |
| WO2010015522A1 (en) | 2008-08-08 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy-substituted heterocyclics, medicines containing these compounds and method for the production thereof |
| TWI577664B (en) | 2009-01-16 | 2017-04-11 | 艾克塞里克斯公司 | Malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, pharmaceutical composition comprising the same and use thereof |
| SI2451445T1 (en) | 2009-07-06 | 2019-07-31 | Boehringer Ingelheim International Gmbh | Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
| UA108618C2 (en) | 2009-08-07 | 2015-05-25 | APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT | |
| KR101317809B1 (en) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cell and non-metalic salt lubricant |
| KR20140096571A (en) | 2013-01-28 | 2014-08-06 | 한미약품 주식회사 | Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one |
| KR101645112B1 (en) | 2013-03-06 | 2016-08-02 | 아스트라제네카 아베 | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor |
| US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
| CN106132953B (en) * | 2014-04-04 | 2019-03-22 | H.隆德贝克有限公司 | Quinazoline-THF- the amine of halogenation as PDE1 inhibitor |
| US20170176028A1 (en) | 2015-12-18 | 2017-06-22 | Lg Electronics Inc. | Air conditioner |
| BR112019010020A2 (en) | 2016-11-17 | 2019-08-20 | Univ Texas | compounds with anti-tumor activity against cancer cells containing egfr or her2 exon mutations |
| CN112321814B (en) * | 2020-12-30 | 2021-03-23 | 广州初曲科技有限公司 | Preparation and application of gefitinib idebenone conjugate |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| SK285141B6 (en) * | 1996-02-13 | 2006-07-07 | Astrazeneca Uk Limited | Use of quinazoline derivative, quinazoline derivative, process for preparation thereof and pharmaceutical composition containing thereof |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| KR100489174B1 (en) * | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-anilinoquinazoline derivatives |
| DK0892789T4 (en) * | 1996-04-12 | 2010-04-06 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| DE19911509A1 (en) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
-
2000
- 2000-08-26 DE DE10042058A patent/DE10042058A1/en not_active Ceased
-
2001
- 2001-08-18 IL IL15460201A patent/IL154602A0/en unknown
- 2001-08-18 CA CA002417897A patent/CA2417897C/en not_active Expired - Fee Related
- 2001-08-18 CN CNB01814635XA patent/CN100404517C/en not_active Expired - Fee Related
- 2001-08-18 MX MXPA03001483A patent/MXPA03001483A/en active IP Right Grant
- 2001-08-18 EA EA200300219A patent/EA005679B1/en not_active IP Right Cessation
- 2001-08-18 RS YU14003A patent/RS52279B/en unknown
- 2001-08-18 SK SK231-2003A patent/SK287747B6/en not_active IP Right Cessation
- 2001-08-18 UA UA2003032533A patent/UA73004C2/en unknown
- 2001-08-18 HU HU0300819A patent/HUP0300819A3/en unknown
- 2001-08-18 KR KR1020037002744A patent/KR100862873B1/en not_active IP Right Cessation
- 2001-08-18 PL PL36024801A patent/PL360248A1/en not_active Application Discontinuation
- 2001-08-18 CZ CZ20030870A patent/CZ302567B6/en not_active IP Right Cessation
- 2001-08-18 EE EEP200300077A patent/EE05269B1/en not_active IP Right Cessation
- 2001-08-18 ME MEP-587/08A patent/MEP58708A/en unknown
- 2001-08-18 EP EP01967285A patent/EP1315705A1/en not_active Ceased
- 2001-08-18 NZ NZ524668A patent/NZ524668A/en not_active IP Right Cessation
- 2001-08-18 WO PCT/EP2001/009532 patent/WO2002018351A1/en active Application Filing
- 2001-08-18 AU AU8769401A patent/AU8769401A/en active Pending
- 2001-08-18 JP JP2002523469A patent/JP4834282B2/en not_active Expired - Fee Related
- 2001-08-18 BR BR0113519-8A patent/BR0113519A/en active Pending
- 2001-08-18 AU AU2001287694A patent/AU2001287694B2/en not_active Ceased
- 2001-08-23 UY UY26903A patent/UY26903A1/en not_active Application Discontinuation
- 2001-08-24 MY MYPI20013985A patent/MY126132A/en unknown
- 2001-08-24 AR ARP010104041A patent/AR033562A1/en not_active Suspension/Interruption
- 2001-08-24 TW TW090120905A patent/TWI294422B/en not_active IP Right Cessation
-
2003
- 2003-02-03 EC EC2003004464A patent/ECSP034464A/en unknown
- 2003-02-05 ZA ZA200300991A patent/ZA200300991B/en unknown
- 2003-02-14 BG BG107559A patent/BG107559A/en active Pending
- 2003-02-24 HR HR20030138A patent/HRP20030138A2/en not_active Application Discontinuation
- 2003-02-24 IL IL154602A patent/IL154602A/en not_active IP Right Cessation
- 2003-02-25 NO NO20030870A patent/NO324866B1/en not_active IP Right Cessation
-
2004
- 2004-01-21 HK HK04100462A patent/HK1057557A1/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR033562A1 (en) | BICYCLIC HETEROCICLES, MEDICATIONS CONTAINING THESE COMPOUNDS, THEIR EMPLOYMENT AND PROCEDURES FOR THEIR PREPARATION | |
| ES2311023T3 (en) | DERIVATIVES OF QUINAZOLINE AS INHIBITORS OF CINASE. | |
| RU2326869C2 (en) | Pyridazine 3(2h) derivatives as inhibitor of phosphodiesterase 4 (pde4), method of their preparation, pharmaceutical composition and method of treatment | |
| RU2495873C2 (en) | New uracil compound or salt thereof possessing human deoxyuridine triphosphatase | |
| JP4073961B2 (en) | Nitrogen-containing heterocyclic compounds | |
| RU2324684C2 (en) | Pyrimidine derivatives | |
| AR040524A1 (en) | DERIVATIVES OF QUINAZOLINE, DRUGS CONTAINING THESE COMPOUNDS, THEIR EMPLOYMENT AND PROCEDURES FOR THEIR PREPARATION | |
| ES2317923T3 (en) | CINOLINE COMPOUNDS. | |
| BR9810829A (en) | Compound, process for preparing the same, composition, use of a compound or a pharmaceutically acceptable salt thereof or a composition, and process for treating a condition | |
| PE20091429A1 (en) | 4- (4-CYANE-2-THIOARIL) DIHYDROPYRIMIDINONES AS INHIBITORS OF HUMAN NEUTROPHYL ELASTASE (HNE) | |
| BR0309427A (en) | Reuse of a (2z) -2-cyano-3-hydroxy-n- [4- (trifluoromethyl) phenyl] -2-heptan-6-ylamide or 5- (3-butynyl) -n- [4- (trifluoromethyl) phenyl] -4-isoxazolec rbo-amide | |
| RU2004135064A (en) | NEW SUBSTITUTED INDOS | |
| RU2011139321A (en) | JAK KINASE-MODULATING KINAZOLE KINAZOLE DERIVATIVES AND METHODS OF APPLICATION | |
| CY1107539T1 (en) | Quinazoline derivatives | |
| UY25131A1 (en) | DERIVATIVES OF ARILOXIARILSULFONILAMINO HIDROXAMICOS ACIDS | |
| BR9814116A (en) | Use of quinazoline derivatives as tyrosine kinase inhibitors for the treatment of colonic polyp | |
| UA50792C2 (en) | 7б-(о-AMINOALKYL)-ESTRATRIENES AND PHARMACEUTICAL PREPARATION CONTAINING THEM | |
| DE69709319D1 (en) | 4-ANILINOQUINAZOLINE DERIVATIVES | |
| CY1106134T1 (en) | COMPOSITION OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST AND A DIURETIC AND ITS USE FOR THE TREATMENT OF HYPERTENSION | |
| AP2004003059A0 (en) | Salt forms of E-2-methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer | |
| BR0308145A (en) | Compound, pharmaceutical composition, use of a compound, and process for preparing a compound | |
| JP2006521382A (en) | AKT (protein kinase B) inhibitor | |
| DE69307875D1 (en) | ACYLAMINOINDOL DERIVATIVES AS 5-HT1 AGONISTS | |
| PE20021074A1 (en) | DERIVATIVES OF N-OXIANTRANILAMIDE AND THE MEDICINES THAT CONTAIN THEM | |
| BR0311315A (en) | Aromatic sulphones and their medical use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |